Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agentsVittorio Emanuele Muccio, Paola Omedè, Antonio Palumbo et al.|Cytometry Part B Clinical Cytometry|2015Cited by 54
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysisStefania Oliva, Paola Omedè, Concetta Conticello et al.|Oncotarget|2016Cited by 36
Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapiesS Caltagirone, Paola Omedè, Simona Aschero et al.|Haematologica|2014Cited by 22
A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) PatientsSara Bringhen, Mario Boccadoro, Pieter Sonneveld et al.|Blood|2016Cited by 7
Clinical impact of immunophenotypic remission after allogeneic hematopoietic cell transplantation in multiple myelomaLuisa Giaccone, Benedetto Bruno, Paola Omedè et al.|Bone Marrow Transplantation|2015Cited by 6